ArticleBMC cancer2023

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.

Danyang Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.